Originally published byEU-Startups
BioLamina, a Stockholm-based BioTech scale-up specialising in matrix biology and cell culture, has secured a €20 million financing commitment from the European Investment Bank (EIB) to enable cell therapies for serious chronic diseases. The EIB loan is structured as venture debt, a form of long-term financing aimed at innovative, rapidly expanding companies. It complements venture […]
The post Stockholm’s BioLamina secures €20 million EIB loan to scale cell therapies for chronic diseases appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
Intel eases reliance on TSMC with 'Merica-made Core Series 3 processors
April 17, 2026
Cloudflare can remember it for you wholesale
April 18, 2026
Opsec oopsie: Dutch navy frigate location outed by mailing it a Bluetooth tracker
April 17, 2026
Britain puts €573 million on the table as Sovereign AI names its first startup cohort
April 17, 2026
CamGraPhIC lands €211 million to tackle AI’s data bottleneck – in one of Italy’s largest DeepTech funding deals
April 15, 2026